NCT05215951 - Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 19, 2022

Primary Completion Date

March 9, 2023

Study Completion Date

March 9, 2023

Conditions

Lung Cancer

Interventions

DRUG

osimertinib

Dose Formulation: tablet； Dosage Level(s): osimertinib 80 mg QD for oral administration; Dosage formulation, dose reduction:40 mg QD for oral administration

Trial Locations (6)

150049

Research Site, Harbin

450000

Research Site, Zhengzhou

610041

Research Site, Chengdu

621000

Research Site, Mianyang

637000

Research Site, Nanchong

644000

Research Site, Yibin